

# cancer | innova

BUSINESS FACTORY  
MEDICINES



XUNTA DE GALICIA  
VICEPRESIDENCIA SEGUNDA E  
CONSELLERÍA DE ECONOMÍA,  
EMPRESA E INNOVACIÓN



# CANCER INNOVA PROGRAM SPAIN

Pioneer program in Spain/inclusive structure connected to Cancer Mission of Horizon EU (2021-2027)

Unique inclusive partnership structure with the joint participation of **private and public entities** and all the involved stakeholders for **promoting cancer innovation**




Patient associations	Scientific Foundation of the Spanish Cancer Association (AECC). The biggest patient association in Spain.
Disruptive research	Disruptive research programs on cancer identified through Expression of interest calls.
Kærtor Foundation	Validated high-efficiency methodology in drug discovery with more than 20 years of experience and 15 New Chemical Entities (NCE) advanced to clinical trials. .
Companies R&D	The first global industrial driver pharmaceutical company. Open to the incorporation of selected companies.
Venture Capital	Six specialized investment companies in the drug discovery field.
Investors	Investment based on tax benefits without retaining any generated property in the first stages.
Public administration	Gain. Pioneer in the country in supporting Open Innovation programs


# CANCER INNOVA PROGRAM

AECC INNOVA 2020 // PROGRAMA INNOVACIÓN


## INNOVACIÓN PROGRAMA TRANSVERSAL



# Business Factory Medicines



# ROAD MAP TO PRECLINICAL CANDIDATE FK-087 XX inhibitor



# EoI PRIORITIZATION PROCEDURE



## Expression of interest application form


**SUBMISSION OF DOCUMENTS AND APPLICATION REVIEW PROCESS:**  
 Upon receipt, Cancer Innovation will provide an email acknowledging receipt of documents. Every document will be independently reviewed by 2 Cancer Innovation EoI ACCO including external advisors with expertise in drug discovery and drug development/development in the field. Associated costs will include the cost of the external advisors for the review of the EoI.

All this information will be treated based on the Confidentiality Policy established by the Cancer Foundation and FCACCC.

**A. Descriptive title of the research project**

**B. Applicant contact details**  
 Name of principal researcher(s)  
 Category  
 Department  
 Centre  
 University  
 Address  
 Telephone  
 Email address  
 Transfer Office

EoI



Task	Available	External availability / implementation	Description
1. Primary assay development		-	In vitro enzymatic assay. No description in the EoI
2. Secondary assay development		X	
2.1 Translational	X	X	
2.2 Other		-	Neither efficacy nor selectivity assay are reported.
3. Companion patient stratification			
3.1 Genomics	X	-	Gene expression profile
3.2 Proteomics	X	-	Protein methylation, Serum biomarkers
3.3 Metabolomics	X	X	
3.4 Microbiome	X	X	
4. Connection with other programs (through Karlar)			• FK11 (XX inhibitors for cancer treatment) Connection to XX targets and to medicinal chemistry • FK03 (novel biomarkers for AD and MC), Task 3.2
5. Connection with translational methodologies (Biomimetic)		X	
6. Chemistry/ML		-	
7. Agreement feasibility			

List of selected projects for incubation




Experts for each key go/no go experiments + PI EoI



## ROAD MAP TO PRECLINICAL CANDIDATE

Companion stratification





# Thank you for your attention!

<https://www.cancerinnova.com/>

**cancer** |  
**innova** | BUSINESS FACTORY  
MEDICINES